155 related articles for article (PubMed ID: 27625046)
1. In vitro inhibition of human papillomavirus following use of a carrageenan-containing vaginal gel.
Novetsky AP; Keller MJ; Gradissimo A; Chen Z; Morgan SL; Xue X; Strickler HD; Fernández-Romero JA; Burk R; Einstein MH
Gynecol Oncol; 2016 Nov; 143(2):313-318. PubMed ID: 27625046
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of Carraguard, a vaginal microbicide, in protecting women against high-risk human papillomavirus infection.
Marais D; Gawarecki D; Allan B; Ahmed K; Altini L; Cassim N; Gopolang F; Hoffman M; Ramjee G; Williamson AL
Antivir Ther; 2011; 16(8):1219-26. PubMed ID: 22155903
[TBL] [Abstract][Full Text] [Related]
3. Design and methods for the Carrageenan-gel Against Transmission of Cervical Human papillomavirus (CATCH) study: A randomized controlled trial.
Laurie C; Tota JE; El-Zein M; Tellier PP; Coutlée F; Burchell AN; Franco EL
Contemp Clin Trials; 2021 Nov; 110():106560. PubMed ID: 34487919
[TBL] [Abstract][Full Text] [Related]
4. Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: first experimental results.
Perino A; Consiglio P; Maranto M; De Franciscis P; Marci R; Restivo V; Manzone M; Capra G; Cucinella G; Calagna G
Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6744-6752. PubMed ID: 31378918
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase 1, randomized, placebo-controlled first-in-human trial of griffithsin formulated in a carrageenan vaginal gel.
Teleshova N; Keller MJ; Fernández Romero JA; Friedland BA; Creasy GW; Plagianos MG; Ray L; Barnable P; Kizima L; Rodriguez A; Cornejal N; Melo C; Cruz Rodriguez G; Mukhopadhyay S; Calenda G; Sinkar SU; Bonnaire T; Wesenberg A; Zhang S; Kleinbeck K; Palmer K; Alami M; O'Keefe BR; Gillevet P; Hur H; Liang Y; Santone G; Fichorova RN; Kalir T; Zydowsky TM
PLoS One; 2022; 17(1):e0261775. PubMed ID: 35051209
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo evaluation of two carrageenan-based formulations to prevent HPV acquisition.
Rodríguez A; Kleinbeck K; Mizenina O; Kizima L; Levendosky K; Jean-Pierre N; Villegas G; Ford BE; Cooney ML; Teleshova N; Robbiani M; Herold BC; Zydowsky T; Fernández Romero JA
Antiviral Res; 2014 Aug; 108():88-93. PubMed ID: 24909570
[TBL] [Abstract][Full Text] [Related]
7. Effect of sexual intercourse on the absorption of levonorgestrel after vaginal administration of 0.75 mg in Carraguard gel: a randomized, cross-over, pharmacokinetic study.
Brache V; Croxatto H; Kumar N; Sitruk-Ware R; Cochón L; Schiappacasse V; Sivin I; Muñoz C; Maguire R; Faundes A
Contraception; 2009 Feb; 79(2):150-4. PubMed ID: 19135574
[TBL] [Abstract][Full Text] [Related]
8. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide.
Coggins C; Blanchard K; Alvarez F; Brache V; Weisberg E; Kilmarx PH; Lacarra M; Massai R; Mishell D; Salvatierra A; Witwatwongwana P; Elias C; Ellertson C
Sex Transm Infect; 2000 Dec; 76(6):480-3. PubMed ID: 11221133
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of a carrageenan gel in preventing anal human papillomavirus (HPV) infection: interim analysis of the Lubricant Investigation in Men to Inhibit Transmission of HPV Infection (LIMIT-HPV) randomised controlled trial.
Laurie C; El-Zein M; Tota JE; Khosrow-Khavar F; Tellier PP; Coutlée F; de Pokomandy A; Franco EL;
Sex Transm Infect; 2022 Jun; 98(4):239-246. PubMed ID: 34140405
[TBL] [Abstract][Full Text] [Related]
10. UC781 microbicide gel retains anti-HIV activity in cervicovaginal lavage fluids collected following twice-daily vaginal application.
Haaland RE; Evans-Strickfaden T; Holder A; Pau CP; McNicholl JM; Chaikummao S; Chonwattana W; Hart CE
Antimicrob Agents Chemother; 2012 Jul; 56(7):3592-6. PubMed ID: 22508307
[TBL] [Abstract][Full Text] [Related]
11. Assessment of the possible inhibitory effect of carrageenan in human papillomavirus DNA testing by polymerase chain reaction amplification.
Laurie C; El-Zein M; Franco EL; Coutlée F
J Med Virol; 2021 Nov; 93(11):6408-6411. PubMed ID: 33760280
[TBL] [Abstract][Full Text] [Related]
12. Acceptability of a carrageenan-based candidate vaginal microbicide and matching placebo: findings from a phase II safety trial among women in Chiang Rai, Thailand.
Jones HE; Chaikummao S; van de Wijgert JH; Friedland BA; Manopaiboon C; Witwatwongwana P; Wankrairot M; Chantharojwong N; Kilmarx PH
J Womens Health (Larchmt); 2009 Jul; 18(7):1003-10. PubMed ID: 19575689
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of a Carrageenan gel Against Transmission of Cervical HPV (CATCH): interim analysis of a randomized, double-blind, placebo-controlled, phase 2B trial.
Magnan S; Tota JE; El-Zein M; Burchell AN; Schiller JT; Ferenczy A; Tellier PP; Coutlée F; Franco EL;
Clin Microbiol Infect; 2019 Feb; 25(2):210-216. PubMed ID: 29684633
[TBL] [Abstract][Full Text] [Related]
14. First-in-Human Trial of MIV-150 and Zinc Acetate Coformulated in a Carrageenan Gel: Safety, Pharmacokinetics, Acceptability, Adherence, and Pharmacodynamics.
Friedland BA; Hoesley CJ; Plagianos M; Hoskin E; Zhang S; Teleshova N; Alami M; Novak L; Kleinbeck KR; Katzen LL; Zydowsky TM; Fernández-Romero JA; Creasy GW
J Acquir Immune Defic Syndr; 2016 Dec; 73(5):489-496. PubMed ID: 27437826
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a self-applied carrageenan-based gel to prevent human papillomavirus infection in sexually active young women (CATCH study): an exploratory phase IIB randomised, placebo-controlled trial.
Laurie C; El-Zein M; Botting-Provost S; Tota JE; Tellier PP; Coutlée F; Burchell AN; Franco EL
EClinicalMedicine; 2023 Jun; 60():102038. PubMed ID: 37396806
[TBL] [Abstract][Full Text] [Related]
16. A randomized, placebo-controlled trial to assess the safety and acceptability of use of carraguard vaginal gel by heterosexual couples in Thailand.
Kilmarx PH; Blanchard K; Chaikummao S; Friedland BA; Srivirojana N; Connolly C; Witwatwongwana P; Supawitkul S; Mock PA; Chaowanachan T; Tappero J
Sex Transm Dis; 2008 Mar; 35(3):226-32. PubMed ID: 18490865
[TBL] [Abstract][Full Text] [Related]
17. Colposcopic evaluation of a vaginal gel formulation of iota-carrageenan.
Elias CJ; Coggins C; Alvarez F; Brache V; Fraser IS; Lacarra M; Lähteenmäki P; Massai R; Mishell DR; Phillips DM; Salvatierra AM
Contraception; 1997 Dec; 56(6):387-9. PubMed ID: 9494773
[TBL] [Abstract][Full Text] [Related]
18. An intravaginal ring that releases three antiviral agents and a contraceptive blocks SHIV-RT infection, reduces HSV-2 shedding, and suppresses hormonal cycling in rhesus macaques.
Derby N; Aravantinou M; Kenney J; Ugaonkar SR; Wesenberg A; Wilk J; Kizima L; Rodriguez A; Zhang S; Mizenina O; Levendosky K; Cooney ML; Seidor S; Gettie A; Grasperge B; Blanchard J; Piatak M; Lifson JD; Fernández-Romero J; Zydowsky TM; Robbiani M
Drug Deliv Transl Res; 2017 Dec; 7(6):840-858. PubMed ID: 28600625
[TBL] [Abstract][Full Text] [Related]
19. Effect of Replens gel used with a diaphragm on tests for human papillomavirus and other lower genital tract infections.
Smith-McCune KK; Tuveson JL; Rubin MM; Da Costa MM; Darragh TM; Shiboski SC; Van Der Pol B; Moscicki AB; Palefsky JM; Sawaya GF
J Low Genit Tract Dis; 2006 Oct; 10(4):213-8. PubMed ID: 17012985
[TBL] [Abstract][Full Text] [Related]
20. Carrageenan is a potent inhibitor of papillomavirus infection.
Buck CB; Thompson CD; Roberts JN; Müller M; Lowy DR; Schiller JT
PLoS Pathog; 2006 Jul; 2(7):e69. PubMed ID: 16839203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
